The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis

Imagem de Miniatura
Arquivos
art_BEZERRA-SOUZA_The_antifungal_compound_butenafine_eliminates_promastigote_and_amastigote_2016.PDF (805.31 KB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
PASSERO, Luiz Felipe D.
Citação
PARASITOLOGY INTERNATIONAL, v.65, n.6, p.702-707, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The production of ergosterol lipid, important for the Leishmania membrane homeostasis, involves different enzymes. This pathway can be blocked to azoles and allylamines drugs, such as Butenafine. The aim of the present work was to evaluate the anti-leishmanicidal activity of this drug in 2 major species of Leishmania responsible for causing the American tegumentar leishmaniasis (L (L.) amazonensis and L (V.) braziliensis). Butenafine eliminated promastigote forms of L amazonensis and L braziliensis with efficacy similar to miltefosine, a standard anti-leishmania drug. In addition, butenafine induced alterations in promastigote forms of L amazonensis that resemble programmed cell death. Butenafine as well as miltefosine presented mild toxicity in peritoneal macrophages, however, butenafine was more effective to eliminate intracellular amastigotes of both L amazonensis and L braziliensis, and this effect was not associated with elevated levels of nitric oxide or hydrogen peroxide. Taken together, data presented herein suggests that butenafine can be considered as a prototype drug able to eliminate L amazonensis and L braziliensis, etiological agents of anergic diffuse and mucocutaneous leishmaniasis, respectively.
Palavras-chave
Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, Butenafine, Antileishmanial agent, Drug repurposing
URI
https://observatorio.fm.usp.br/handle/OPI/17170
Referências
  1. Ait-Oudhia K, 2012, VET PARASITOL, V187, P386, DOI 10.1016/j.vetpar.2012.01.034
  2. Andrade-Neto VV, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1467-8
  3. Arnoult D, 2002, CELL DEATH DIFFER, V9, P65, DOI 10.1038/sj.cdd.4400951
  4. BERMAN JD, 1986, MOL BIOCHEM PARASIT, V20, P85, DOI 10.1016/0166-6851(86)90145-3
  5. BERMAN JD, 1987, J PARASITOL, V73, P671, DOI 10.2307/3282158
  6. BERMAN JD, 1984, MOL BIOCHEM PARASIT, V12, P1, DOI 10.1016/0166-6851(84)90039-2
  7. Chattopadhyay A, 2011, BIOCHEM BIOPH RES CO, V416, P7, DOI 10.1016/j.bbrc.2011.11.023
  8. Das Sudip, 2010, Indian Dermatol Online J, V1, P8, DOI 10.4103/2229-5178.73249
  9. Lima LVD, 2014, PATHOG GLOB HEALTH, V108, P381, DOI 10.1179/2047773214Y.0000000166
  10. Passero LFD, 2009, PARASITOL RES, V105, P1741, DOI 10.1007/s00436-009-1614-7
  11. Dorlo TPC, 2012, ANALYST, V137, P1265, DOI 10.1039/c2an15641e
  12. Dorlo TPC, 2012, J ANTIMICROB CHEMOTH, V67, P2576, DOI 10.1093/jac/dks275
  13. Elmahallawy E.K., 2015, CLIN INFECT DIS, V60, P1398
  14. Fde A., 2011, MEM I O CRUZ, V106, P507
  15. Freitas-Junior LH, 2012, INT J PARASITOL-DRUG, V2, P11, DOI 10.1016/j.ijpddr.2012.01.003
  16. GOAD LJ, 1989, MOL BIOCHEM PARASIT, V32, P179, DOI 10.1016/0166-6851(89)90069-8
  17. Hernandez-Chinea C, 2015, PARASITOL INT, V64, P479, DOI 10.1016/j.parint.2015.06.011
  18. Khademvatan S, 2011, KOREAN J PARASITOL, V49, P17, DOI 10.3347/kjp.2011.49.1.17
  19. Klug DM, 2016, BIOORG MED CHEM LETT, V26, P2569, DOI 10.1016/j.bmcl.2016.03.103
  20. Kulkarni MM, 2013, PARASITOL RES, V112, P2095, DOI 10.1007/s00436-013-3274-x
  21. Pandharkar T, 2014, ANTIMICROB AGENTS CH, V58, P4682, DOI 10.1128/AAC.02405-14
  22. Paris C, 2004, ANTIMICROB AGENTS CH, V48, P852, DOI 10.1128/AAC.48.3.852-859.2004
  23. Passero Luiz Felipe Domingues, 2014, Curr Clin Pharmacol, V9, P187
  24. Perry M, 2015, LANCET, V385, P80
  25. Purkait B, 2015, J ANTIMICROB CHEMOTH, V70, P1343, DOI 10.1093/jac/dku534
  26. Rangel H, 1996, ANTIMICROB AGENTS CH, V40, P2785
  27. Sampaio Raimunda Nonata Ribeiro, 2003, Rev. Soc. Bras. Med. Trop., V36, P531, DOI 10.1590/S0037-86822003000400018
  28. Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x
  29. Simoes-Mattos L, 2002, VET PARASITOL, V103, P207, DOI 10.1016/S0304-4017(01)00595-7
  30. Sudip D., 2010, INDIAN DERMATOL ONLI, V1, P8
  31. Sundar S, 2015, EXPERT OPIN PHARMACO, V16, P237, DOI 10.1517/14656566.2015.973850
  32. Thakur CP, 1999, T ROY SOC TROP MED H, V93, P319, DOI 10.1016/S0035-9203(99)90037-8
  33. VANNIERSANTOS MA, 1995, J EUKARYOT MICROBIOL, V42, P337, DOI 10.1111/j.1550-7408.1995.tb01591.x
  34. Verma NK, 2004, ANTIMICROB AGENTS CH, V48, P3010, DOI 10.1128/AAC.48.8.3010-3015.2004
  35. Yamamoto ES, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144946
  36. Yamamoto ES, 2014, PARASITOL RES, V113, P333, DOI 10.1007/s00436-013-3659-x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - LIM/50
Artigos e Materiais de Revistas Científicas - LIM/60